Products

Nilotinib Hydrochloride (CAS 923288-95-3) is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with the molecular formula C₂₈H₂₃ClF₃N₇O and a molecular weight of 565.98 g/mol. The molecule features a benzamide core with a 4-methyl-1H-imidazol-1-yl group, a trifluoromethyl substituent, and a pyridin-3-yl pyrimidinyl amino group.

Lenvatinib Mesylate (CAS 857890-39-2) is the methanesulfonate salt of lenvatinib, an orally bioavailable, small-molecule multikinase inhibitor with the molecular formula C₂₂H₂₃ClN₄O₇S and a molecular weight of 522.96 g/mol. The molecule features a quinoline carboxamide core with a 3-chloro-4-(3-cyclopropylureido)phenoxy substituent at the 4-position and a methoxy group at the 7-position.

Dasatinib (CAS 302962-49-8) is a potent, oral, multi-targeted tyrosine kinase inhibitor developed as a second-generation Bcr-Abl inhibitor to overcome imatinib resistance. Chemically known as N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, Dasatinib features a complex heterocyclic architecture incorporating a thiazole-5-carboxamide core linked to a chloromethylphenyl group and a pyrimidine-piperazine side chain.

Imatinib Mesylate (CAS 220127-57-1) is the methanesulfonate salt of imatinib, a small-molecule tyrosine kinase inhibitor that revolutionized the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Chemically known as N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate.

Crizotinib (CAS 877399-52-5) is an orally bioavailable, ATP‑competitive inhibitor of the receptor tyrosine kinases c‑Met (hepatocyte growth factor receptor) and anaplastic lymphoma kinase (ALK). The molecule features a pyridin‑2‑amine core with a piperidin‑4‑yl‑pyrazole substituent and a dichlorofluorophenyl‑ethoxy side chain.

Ruxolitinib (CAS 941678-49-5) is a potent, orally bioavailable, and selective dual inhibitor of Janus kinases 1 and 2 (JAK1/JAK2). The molecule features a pyrrolo[2,3‑d]pyrimidine core with a cyclopentyl and pyrazole‑containing side chain. This unique structural architecture enables Ruxolitinib to inhibit JAK1 with an IC₅₀ of 3.3 nM and JAK2 with an IC₅₀ of 2.8 nM in cell‑free assays.